JCI - Citations to PPARγ ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis

Citations to this article

PPARγ ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis

Dipak Panigrahy, … , Judah Folkman, Arja Kaipainen

Dipak Panigrahy, … , Judah Folkman, Arja Kaipainen

Published October 1, 2002
Citation Information: J Clin Invest. 2002;110(7):923-932. https://doi.org/10.1172/JCI15634.

View: Text | PDF

Article Development

Total citations by year

Year:	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	Total
Citations:	2	9	5	5	6	4	4	5	7	8	9	8	4	14	11	11	5	19	6	6	3	5	3	159

Citation information

Citations to this article (159)

Title and authors	Publication	Year
The role and mechanism of aerobic glycolysis in nasopharyngeal carcinoma Pan Z, Liu Y, Li H, Qiu H, Zhang P, Li Z, Wang X, Tian Y, Feng Z, Zhu S, Wang X	PeerJ	2025
Rosiglitazone-Mediated Activation of PPARγ Induces PlGF Expression in Trophoblast Cells. Nandi P, Halari C, Lee M, Prabaharan E, Sarajideen S, Lee DK, Drewlo S	Reproductive sciences (Thousand Oaks, Calif.)	2025
Discovery of new thiazolidine-2,4-dione derivatives as potential VEGFR-2 inhibitors: In vitro and in silico studies Eissa IH, Elkady H, Rashed M, Elwan A, Hagras M, Dahab MA, Taghour MS, Ibrahim IM, Husein DZ, Elkaeed EB, Al-ghulikah HA, Metwaly AM, Mahdy HA	Heliyon	2024
Structure-Activity Relationship Study and Design Strategies of Hydantoin, Thiazolidinedione, and Rhodanine-Based Kinase Inhibitors: A Two-Decade Review. Naufal M, Hermawati E, Syah YM, Hidayat AT, Hidayat IW, Al-Anshori J	ACS Omega	2024
Use of drugs for hyperlipidaemia and diabetes and risk of primary and secondary brain tumours: nested case–control studies using the UK Clinical Practice Research Datalink (CPRD) Robinson JW, Martin R, Ozawa M, Elwenspoek MM, Redaniel MT, Kurian K, Ben-Shlomo Y	BMJ Open	2024
PPARG activation promotes the proliferation of colorectal cancer cell lines and enhances the antiproliferative effect of 5-fluorouracil Schöckel L, Woischke C, Surendran SA, Michl M, Schiergens T, Hölscher A, Glass F, Kreissl P, Klauschen F, Günther M, Ormanns S, Neumann J	BMC Cancer	2024
An insight into thymidylate synthase inhibitor as anticancer agents: an explicative review. Sen A, Karati D	Naunyn-Schmiedeberg's Archives of Pharmacology	2024
Peroxisome proliferator-activated receptors: Key regulators of tumor progression and growth Asgharzadeh F, Memarzia A, Alikhani V, Beigoli S, Boskabady MH	Translational oncology	2024
Cladosporols and PPARγ: Same Gun, Same Bullet, More Targets Rapuano R, Mercuri A, Dallavalle S, Moricca S, Lavecchia A, Lupo A	Biomolecules	2024
Specific Deletions of Chromosomes 3p, 5q, 13q, and 21q among Patients with G2 Grade of Non-Small Cell Lung Cancer Kolecka-Bednarczyk A, Frydrychowicz M, Budny B, Ruciński M, Dompe C, Gabryel P, Płachno BJ, Ruchała M, Ziemnicka K, Zieliński P, Budna-Tukan J	International Journal of Molecular Sciences	2024
In silico analysis of polyphenols modulate bovine PPARγ to increase milk fat synthesis in dairy cattle via the MAPK signaling pathways Safdar M, Hassan F, Khan MS, Khan AH, Junejo Y, Ozaslan M, Arain MA, Behan AA	Journal of Animal Science	2024
PPARs and the Kynurenine Pathway in Melanoma—Potential Biological Interactions Walczak K, Gerkowicz A, Krasowska D	International journal of molecular sciences	2023
Dihydropyrimidone Derivatives as Thymidine Phosphorylase Inhibitors: Inhibition Kinetics, Cytotoxicity, and Molecular Docking Cui TM, Altaf M, Aldarhami A, Bazaid AS, Saeedi NH, Alkayyal AA, Alshabrmi FM, Ali F, Aladhadh M, Khan MY, Alsaiari AA, Ma YR	Molecules (Basel, Switzerland)	2023
Loss of PPARγ activity characterizes early protumorigenic stromal reprogramming and dictates the therapeutic window of opportunity Caruso JA, Wang X, Murrow LM, Rodriguez CI, Chen-Tanyolac C, Vu L, Chen YY, Gascard P, Gartner ZJ, Kerlikowske K, Tlsty TD	Proceedings of the National Academy of Sciences	2023
Design, synthesis, docking, ADMET and anticancer evaluations of N-alkyl substituted iodoquinazoline derivatives as dual VEGFR-2 and EGFR inhibitors Alsulaimany M, El-Adl K, Aljohani AK, Alharbi HY, Alatawi OM, Aljohani MS, El-morsy A, Almadani SA, Alsimaree AA, Salama SA, Keshek DE, Mohamed AA	RSC Advances	2023
Peroxisome proliferator-activated receptors as therapeutic target for cancer. Wang Y, Lei F, Lin Y, Han Y, Yang L, Tan H	Journal of Cellular and Molecular Medicine	2023
Design, Molecular Docking, Synthesis, Anticancer and Anti-Hyperglycemic Assessments of Thiazolidine-2,4-diones Bearing Sulfonylthiourea Moieties as Potent VEGFR-2 Inhibitors and PPARγ Agonists. Abdelgawad MA, El-Adl K, El-Hddad SSA, Elhady MM, Saleh NM, Khalifa MM, Khedr F, Alswah M, Nayl AA, Ghoneim MM, Abd El-Sattar NEA	Pharmaceuticals (Basel, Switzerland)	2022
Design, synthesis, in silico docking, ADMET and anticancer evaluations of thiazolidine-2,4-diones bearing heterocyclic rings as dual VEGFR-2/EGFRT790M tyrosine kinase inhibitors Aziz NA, George RF, El-Adl K, Mahmoud WR	RSC Advances	2022
Peroxisome Proliferator-Activated Receptors and the Hallmarks of Cancer Wagner N, Wagner KD	Cells	2022
Potential Therapeutic Effects of Thiazolidinedione on Malignant Glioma Sheu ML, Pan LY, Hu HY, Su HL, Sheehan J, Tsou HK, Pan HC	International journal of molecular sciences	2022
A Scoping Review of the Use of Pioglitazone in the Treatment of Temporo-Mandibular Joint Arthritis Turosz N, Chęcińska K, Chęciński M, Kamińska M, Nowak Z, Sikora M, Chlubek D	International journal of environmental research and public health	2022
Rethinking pioglitazone as a cardioprotective agent: a new perspective on an overlooked drug L Nesti, D Tricò, A Mengozzi, A Natali	Cardiovascular Diabetology	2021
MicroRNAs: The Link between the Metabolic Syndrome and Oncogenesis A Fodor, AL Lazar, C Buchman, B Tiperciuc, OH Orasan, A Cozma	International journal of molecular sciences	2021
Abscisic acid regulates dormancy of prostate cancer disseminated tumor cells in the bone marrow Y Jung, FC Cackowski, K Yumoto, AM Decker, Y Wang, M Hotchkin, E Lee, L Buttitta, RS Taichman	Neoplasia (New York, N.Y.)	2021
How cancer cells remodel lipid metabolism: strategies targeting transcription factors DW Jeong, S Lee, YS Chun	Lipids in Health and Disease	2021
Eicosanoid regulation of debris-stimulated metastasis J Deng, H Yang, VM Haak, J Yang, FC Kipper, C Barksdale, SH Hwang, A Gartung, DR Bielenberg, S Subbian, KK Ho, X Ye, D Fan, Y Sun, BD Hammock, D Panigrahy	Proceedings of the National Academy of Sciences	2021
Repurposing new drug candidates and identifying crucial molecules underlying PCOS Pathogenesis Based On Bioinformatics Analysis Dehghan Z, Mohammadi-Yeganeh S, Sameni M, Mirmotalebisohi SA, Zali H, Salehi M	DARU Journal of Pharmaceutical Sciences	2021
Role of Caveolin-1 in Diabetes and Its Complications D Haddad, AA Madhoun, R Nizam, F Al-Mulla	Oxidative medicine and cellular longevity	2020
The Emerging Role of PPAR Beta/Delta in Tumor Angiogenesis S Du, N Wagner, KD Wagner	PPAR Research	2020
PPARs and Angiogenesis—Implications in Pathology N Wagner, KD Wagner	International journal of molecular sciences	2020
Differential Effects of Cancer-Associated Mutations Enriched in Helix H3 of PPARγ Jang DM, Jang JY, Kim HJ, Han BW	Cancers	2020
Pro-Survival Lipid Sphingosine-1-Phosphate Metabolically Programs T Cells to Limit Anti-tumor Activity P Chakraborty, SG Vaena, K Thyagarajan, S Chatterjee, A Al-Khami, SP Selvam, H Nguyen, I Kang, MW Wyatt, U Baliga, Z Hedley, RN Ngang, B Guo, GC Beeson, S Husain, CM Paulos, CC Beeson, MJ Zilliox, EG Hill, M Mehrotra, XZ Yu, B Ogretmen, S Mehrotra	Cell Reports	2019
Chiral phenoxyacetic acid analogues inhibit colon cancer cell proliferation acting as PPARγ partial agonists L Sabatino, P Ziccardi, C Cerchia, L Muccillo, L Piemontese, F Loiodice, V Colantuoni, A Lupo, A Lavecchia	Scientific Reports	2019
Emerging roles of aerobic glycolysis in breast cancer Z Wu, J Wu, Q Zhao, S Fu, J Jin	Clinical and Translational Oncology	2019
Insight of the Interaction between 2,4-thiazolidinedione and Human Serum Albumin: A Spectroscopic, Thermodynamic and Molecular Docking Study. Rahman S, Rehman MT, Rabbani G, Khan P, AlAjmi MF, Hassan MI, Muteeb G, Kim J	International journal of molecular sciences	2019
Synergy between peroxisome proliferator-activated receptor γ agonist and radiotherapy in cancer G Huang, L Yin, J Lan, R Tong, M Li, F Na, X Mo, C Chen, J Xue, Y Lu	Cancer Science	2018
A Synergistic Anti-Cancer Effect of Troglitazone and Lovastatin in a Human Anaplastic Thyroid Cancer Cell Line and in a Mouse Xenograft Model WB Zhong, YC Tsai, LH Chin, JH Tseng, LW Tang, S Horng, YC Fan, SP Hsu	International journal of molecular sciences	2018
Thiazolidinediones and risk of colorectal cancer in patients with diabetes mellitus: A meta-analysis Liu Y, Jin PP, Sun XC, Hu TT	Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association	2018
Synthesis, Structural Characterization, and Antiangiogenic Activity of Polyfluorinated Benzamides Steinebach C, Ambrożak A, Dosa S, Beedie SL, Strope JD, Schnakenburg G, Figg WD, Gütschow M	ChemMedChem	2018
Induction of apoptosis in prostate cancer by ginsenoside Rh2. Tong-Lin Wu T, Tong YC, Chen IH, Niu HS, Li Y, Cheng JT	Oncotarget	2018
PPAR-γ Agonists As Antineoplastic Agents in Cancers with Dysregulated IGF Axis V Vella, ML Nicolosi, S Giuliano, M Bellomo, A Belfiore, R Malaguarnera	Frontiers in Endocrinology	2017
Rosiglitazone drives cavin-2/SDPR expression in adipocytes in a CEBPα-dependent manner B Hansson, C Rippe, D Kotowska, S Wasserstrom, J Säll, O Göransson, K Swärd, KG Stenkula, M Kanzaki	PloS one	2017
Comparison of the effect between pioglitazone and metformin in treating patients with PCOS:a meta-analysis Y Xu, Y Wu, Q Huang	Archives of Gynecology and Obstetrics	2017
Peroxisome Proliferator-Activated Receptor Gamma in Obesity and Colorectal Cancer: the Role of Epigenetics TK Motawi, OG Shaker, MF Ismail, NH Sayed	Scientific Reports	2017
Crosstalk between the Androgen Receptor and PPAR Gamma Signaling Pathways in the Prostate E Olokpa, PE Moss, LM Stewart	PPAR Research	2017
A Normalization-Free and Nonparametric Method Sharpens Large-Scale Transcriptome Analysis and Reveals Common Gene Alteration Patterns in Cancers QG Li, YH He, H Wu, CP Yang, SY Pu, SQ Fan, LP Jiang, QS Shen, XX Wang, XQ Chen, Q Yu, Y Li, C Sun, X Wang, J Zhou, HP Li, YB Chen, QP Kong	Theranostics	2017
Overexpressing STAMP2 attenuates adipose tissue angiogenesis and insulin resistance in diabetic ApoE −/− /LDLR −/− mouse via a PPARγ/CD36 pathway F Wang, L Han, R Qin, Y Zhang, D Wang, ZH Wang, MX Tang, Y Zhang, M Zhong, W Zhang	Journal of Cellular and Molecular Medicine	2017
Identification of HIF-2α-regulated genes that play a role in human microvascular endothelial sprouting during prolonged hypoxia in vitro TD Nauta, M Broek, S Gibbs, TC van der Pouw-Kraan, CB Oudejans, VW van Hinsbergh, P Koolwijk	Angiogenesis	2016
Screening and Biological Effects of Marine Pyrroloiminoquinone Alkaloids: Potential Inhibitors of the HIF-1α/p300 Interaction AK Goey, CH Chau, TM Sissung, KM Cook, DJ Venzon, A Castro, TR Ransom, CJ Henrich, TC McKee, JB McMahon, T Grkovic, MM Cadelis, BR Copp, KR Gustafson, WD Figg	Journal of Natural Products	2016
Peroxisome Proliferator-Activated Receptor γ Expression Is Inversely Associated with Macroscopic Vascular Invasion in Human Hepatocellular Carcinoma HT Hsu, MT Sung, CC Lee, YJ Kuo, CW Chi, HC Lee, CY Hsia	International journal of molecular sciences	2016
FastProject: a tool for low-dimensional analysis of single-cell RNA-Seq data D DeTomaso, N Yosef	BMC bioinformatics	2016
Clinical relevance of peroxisome proliferator-activated receptor-gamma expression in myxoid liposarcoma A Takeuchi, N Yamamoto, T Shirai, K Hayashi, S Miwa, S Munesue, Y Yamamoto, H Tsuchiya	BMC Cancer	2016
Preventing diet-induced obesity in mice by adipose tissue transformation and angiogenesis using targeted nanoparticles Y Xue, X Xu, XQ Zhang, OC Farokhzad, R Langer	Proceedings of the National Academy of Sciences	2016
PPAR γ as a Novel Therapeutic Target in Lung Cancer AT Reddy, SP Lakshmi, RC Reddy	PPAR Research	2016
PPARγ agonists promote differentiation of cancer stem cells by restraining YAP transcriptional activity U Basu-Roy, E Han, K Rattanakorn, A Gadi, N Verma, G Maurizi, PH Gunaratne, C Coarfa, OD Kennedy, MJ Garabedian, C Basilico, A Mansukhani	Oncotarget	2016
Peroxisome Proliferator-Activated Receptor- γ in Thyroid Autoimmunity SM Ferrari, P Fallahi, R Vita, A Antonelli, S Benvenga	PPAR Research	2015
Chemotherapy and Chemoprevention by Thiazolidinediones E Fröhlich, R Wahl	BioMed Research International	2015
The Association between Type 2 Diabetes Mellitus and Women Cancer: The Epidemiological Evidences and Putative Mechanisms KH Joung, JW Jeong, BJ Ku	BioMed Research International	2015
Nuclear Factor Erythroid 2-Related Factor 2 Drives Podocyte-Specific Expression of Peroxisome Proliferator-Activated Receptor Essential for Resistance to Crescentic GN C Henique, G Bollee, O Lenoir, N Dhaun, M Camus, A Chipont, K Flosseau, C Mandet, M Yamamoto, A Karras, E Thervet, P Bruneval, D Nochy, L Mesnard, PL Tharaux	Journal of the American Society of Nephrology : JASN	2015
Peritumoral adipose tissue as a source of inflammatory and angiogenic factors in colorectal cancer S Amor, MC la Cruz, E Ferrero, O García-Villar, V Barrios, N Fernandez, L Monge, AL García-Villalón, M Granado	International Journal of Colorectal Disease	2015
Hormesis: Decoding Two Sides of the Same Coin D Bhakta-Guha, T Efferth	Pharmaceuticals (Basel, Switzerland)	2015
Inhibition of Corneal Neovascularization by Subconjunctival Injection of Fc-Endostatin, a Novel Inhibitor of Angiogenesis J Yoshida, RT Wicks, AI Zambrano, BM Tyler, K Javaherian, R Grossman, YJ Daoud, P Gehlbach, H Brem, WJ Stark	Journal of Ophthalmology	2015
Critical role of PPARγ in myeloid-derived suppressor cell-stimulated cancer cell proliferation and metastasis Zhao T, Du H, Blum JS, Yan C	Oncotarget	2015
Tumor suppressor control of the cancer stem cell niche Kramer K, Wu J, Crowe D	Oncogene	2015
Dual inhibition of cyclooxygenase-2 and soluble epoxide hydrolase synergistically suppresses primary tumor growth and metastasis G Zhang, D Panigrahy, SH Hwang, J Yang, LM Mahakian, HI Wettersten, JY Liu, Y Wang, ES Ingham, S Tam, MW Kieran, RH Weiss, KW Ferrara, BD Hammock	Proceedings of the National Academy of Sciences	2014
Emerging role of the β-catenin-PPARγ axis in the pathogenesis of colorectal cancer L Sabatino, M Pancione, C Votino, T Colangelo, A Lupo, E Novellino, A Lavecchia, V Colantuoni	World journal of gastroenterology : WJG	2014
Stabilized epoxygenated fatty acids regulate inflammation, pain, angiogenesis and cancer G Zhang, S Kodani, BD Hammock	Progress in Lipid Research	2014
Inhibition of Oxygen-Induced Ischemic Retinal Neovascularization with Adenoviral 15-Lipoxygenase-1 Gene Transfer via Up-Regulation of PPAR-γ and Down-Regulation of VEGFR-2 Expression Z Li, T He, K Du, YQ Xing, YM Run, Y Yan, Y Shen, AV Ljubimov	PloS one	2014
Anticancer Activities of Pterostilbene-Isothiocyanate Conjugate in Breast Cancer Cells: Involvement of PPARγ K Nikhil, S Sharan, AK Singh, A Chakraborty, P Roy, R Reddy	PloS one	2014
A Hypothesis Concerning the Biphasic Dose-Response of Tumors to Angiostatin and Endostatin GE Parris	Dose-Response	2014
Pioglitazone inhibits the proliferation and metastasis of human pancreatic cancer cells I Ninomiya, K Yamazaki, K Oyama, H Hayashi, H Tajima, H Kitagawa, S Fushida, T Fujimura, T Ohta	Oncology Letters	2014
Oridonin Inhibits Tumor Growth and Metastasis through Anti-Angiogenesis by Blocking the Notch Signaling Y Dong, T Zhang, J Li, H Deng, Y Song, D Zhai, Y Peng, X Lu, M Liu, Y Zhao, Z Yi, R Ramchandran	PloS one	2014
Epoxyeicosanoids promote organ and tissue regeneration D Panigrahy, BT Kalish, S Huang, DR Bielenberg, HD Le, J Yang, ML Edin, CR Lee, O Benny, DK Mudge, CE Butterfield, A Mammoto, T Mammoto, B Inceoglu, RL Jenkins, MA Simpson, T Akino, FB Lih, KB Tomer, DE Ingber, BD Hammock, JR Falck, VL Manthati, A Kaipainen, PA D'Amore, M Puder, DC Zeldin, MW Kieran	Proceedings of the National Academy of Sciences	2013
Human Rhabdomyosarcoma Cell Lines for Rhabdomyosarcoma Research: Utility and Pitfalls AR Hinson, R Jones, LE Crose, BC Belyea, FG Barr, CM Linardic	Frontiers in Oncology	2013
Differential activation of catalase expression and activity by PPAR agonists: Implications for astrocyte protection in anti-glioma therapy NK Khoo, S Hebbar, W Zhao, SA Moore, FE Domann, ME Robbins	Redox Biology	2013
Peroxisome Proliferator-activated Receptor γ Agonists Induce Cell Cycle Arrest through Transcriptional Regulation of Krüppel-like Factor 4 (KLF4) S Li, Q Zhou, H He, Y Zhao, Z Liu	The Journal of biological chemistry	2013
SOCS3 is an endogenous inhibitor of pathologic angiogenesis A Stahl, JS Joyal, J Chen, P Sapieha, AM Juan, CJ Hatton, DT Pei, CG Hurst, MR Seaward, NM Krah, RJ Dennison, ER Greene, E Boscolo, D Panigrahy, LE Smith	Blood	2012
Anti- and Protumorigenic Effects of PPARγ in Lung Cancer Progression: A Double-Edged Sword H Li, MC Weiser-Evans, R Nemenoff	PPAR Research	2012
PPARgamma inhibits hepatocellular carcinoma metastases in vitro and in mice B Shen, ES Chu, G Zhao, K Man, CW Wu, JT Cheng, G Li, Y Nie, CM Lo, N Teoh, GC Farrell, JJ Sung, J Yu	British Journal of Cancer	2012
The PPAR Gamma Agonist Troglitazone Regulates Erk 1/2 Phosphorylation via a PPARγ-Independent, MEK-Dependent Pathway in Human Prostate Cancer Cells A Bolden, L Bernard, D Jones, T Akinyeke, LV Stewart	PPAR Research	2012
Antiangiogenic Therapy for Ischemic Retinopathies M Al-Latayfeh, PS Silva, JK Sun, LP Aiello	Cold Spring Harbor Perspectives in Medicine	2012
PPARG Epigenetic Deregulation and Its Role in Colorectal Tumorigenesis L Sabatino, A Fucci, M Pancione, V Colantuoni	PPAR Research	2012
Rosiglitazone and Gemcitabine in combination reduces immune suppression and modulates T cell populations in pancreatic cancer SK Bunt, AM Mohr, JM Bailey, PM Grandgenett, MA Hollingsworth	Cancer Immunology, Immunotherapy	2012
Targeting PPARγ Signaling Cascade for the Prevention and Treatment of Prostate Cancer S Sikka, L Chen, G Sethi, AP Kumar	PPAR Research	2012
Proteome Analysis Identified the PPARγ Ligand 15d-PGJ2 as a Novel Drug Inhibiting Melanoma Progression and Interfering with Tumor-Stroma Interaction V Paulitschke, S Gruber, E Hofstätter, V Haudek-Prinz, P Klepeisz, N Schicher, C Jonak, P Petzelbauer, H Pehamberger, C Gerner, R Kunstfeld	PloS one	2012
Mixing of the old with the new: nanoparticle-mediated pioglitazone delivery to enhance therapeutic neovascularization CC Sheng, CC Hong	Arteriosclerosis, thrombosis, and vascular biology	2012
Targeting adipose tissue angiogenesis to enhance insulin sensitivity L Mannerås-Holm, A Krook	Diabetologia	2012
Use of thiazolidinediones and the risk of colorectal cancer in patients with diabetes: a nationwide, population-based, case-control study SW Chen, YT Tsan, JD Chen, HI Hsieh, CH Lee, HH Lin, JD Wang, PC Chen,	Diabetes care	2012
PPARγ agonists target aromatase via both PGE2 and BRCA1 O Margalit, D Wang, RN Dubois	Cancer prevention research (Philadelphia, Pa.)	2012
Regression of Inflammation in Atherosclerosis by the LXR Agonist R211945 E Vucic, C Calcagno, SD Dickson, JH Rudd, K Hayashi, J Bucerius, E Moshier, JS Mounessa, M Roytman, MJ Moon, J Lin, S Ramachandran, T Tanimoto, K Brown, M Kotsuma, S Tsimikas, EA Fisher, K Nicolay, V Fuster, ZA Fayad	JACC: Cardiovascular Imaging	2012
Epoxy-eicosanoids stimulate multi-organ metastasis and tumor dormancy escape in mice Dipak Panigrahy, Matthew L Edin, Craig R. Lee, Sui Huang, Diane R. Bielenberg, Catherine Butterfield, Carmen M. Barnes, Akiko Mammoto, Tadanori Mammoto, Ayala Luria, Ofra Benny, Deviney M. Chaponis, Andrew C. Dudley, Emily R. Greene, Jo-Anne Vergilio, Giorgio Pietramaggiori, Sandra Scherer-Pietramaggiori, Sarah M. Short, Meetu Seth, Fred B. Lih, Kenneth B. Tomer, Jun Yang, Reto A Schwendener, Bruce D. Hammock, John R. Falck, Vijaya L. Manthati, Donald E. Ingber, Arja Kaipainen, Patricia A. D'Amore, Mark W. Kieran, Darryl Craig Zeldin	Journal of Clinical Investigation	2011
Mechanisms of disease: pulmonary arterial hypertension RT Schermuly, HA Ghofrani, MR Wilkins, F Grimminger	Nature Reviews Cardiology	2011
Pleiotropic effects of glitazones: a double edge sword? S Salomone	Frontiers in pharmacology	2011
Effects of Sulfonylureas on Peroxisome Proliferator-Activated Receptor γ Activity and on Glucose Uptake by Thiazolidinediones KW Lee, YH Ku, M Kim, BY Ahn, SS Chung, KS Park	Diabetes & Metabolism Journal	2011
Peroxisome proliferator-activated receptors (PPARs) in dermatology P Sertznig, J Reichrath	Dermato-endocrinology	2011
Molecular Cross-regulation Between PPAR-γ and other Signaling Pathways: Implications for Lung Cancer Therapy AK Reka, MT Goswami, R Krishnapuram, TJ Standiford, VG Keshamouni	Lung cancer (Amsterdam, Netherlands)	2011
Chronic Oral Exposure to Bisphenol A Results in a Nonmonotonic Dose Response in Mammary Carcinogenesis and Metastasis in MMTV-erbB2 Mice S Jenkins, J Wang, I Eltoum, R Desmond, CA Lamartiniere	Environmental Health Perspectives	2011
Regulation of inflammation in cancer by eicosanoids ER Greene, S Huang, CN Serhan, D Panigrahy	Prostaglandins & Other Lipid Mediators	2011
Rosiglitazone, a PPAR-γ agonist, inhibits VEGF secretion by peripheral blood mononuclear cells and ROS production by human leukocytes RT Mattos, AA Bosco, JA Nogueira-Machado	Inflammation Research	2011
Two Endogenous Antiangiogenic Inhibitors, Endostatin and Angiostatin, Demonstrate Biphasic Curves in their Antitumor Profiles K Javaherian, TY Lee, RM Sjin, GE Parris, L Hlatky	Dose-Response	2011
Specific Thiazolidinediones Inhibit Ovarian Cancer Cell Line Proliferation and Cause Cell Cycle Arrest in a PPARγ Independent Manner L Al-Alem, RC Southard, MW Kilgore, TE Curry, I Agoulnik	PloS one	2011
Dual inhibition of PI3K and mTOR inhibits autocrine and paracrine proliferative loops in PI3K/Akt/mTOR-addicted lymphomas AP Bhatt, PM Bhende, SH Sin, D Roy, DP Dittmer, B Damania	Blood	2010
Effect of systemic medications on onset and progression of diabetic retinopathy PS Silva, JD Cavallerano, JK Sun, LM Aiello, LP Aiello	Nature Reviews Endocrinology	2010
Orphan Nuclear Receptors as Targets for Drug Development S Mukherjee, S Mani	Pharmaceutical Research	2010
Potential relevance of bell-shaped and u-shaped dose-responses for the therapeutic targeting of angiogenesis in cancer AR Reynolds	Dose-response : a publication of International Hormesis Society	2010
Anticancer Role of PPARgamma Agonists in Hematological Malignancies Found in the Vasculature, Marrow, and Eyes PJ Simpson-Haidaris, SJ Pollock, S Ramon, N Guo, CF Woeller, SE Feldon, RP Phipps	PPAR Research	2010
Peroxisome proliferator-activated receptor γ and colorectal cancer Y Dai, WH Wang	World journal of gastrointestinal oncology	2010
Anticancer actions of PPARγ ligands: Current state and future perspectives in human lung cancer SW Han, J Roman	World journal of biological chemistry	2010
The investigation of mitogen-activated protein kinase phosphatase-1 as a potential pharmacological target in non-small cell lung carcinomas, assisted by non-invasive molecular imaging CJ Tai, AT Wu, JF Chiou, HJ Jan, HJ Wei, CH Hsu, CT Lin, WT Chiu, CW Wu, HM Lee, WP Deng	BMC Cancer	2010
Inhibition of tumor angiogenesis by oral etoposide D Panigrahy, A Kaipainen, CE Butterfield, DM Chaponis, AM Laforme, J Folkman, MW Kieran	Experimental and therapeutic medicine	2010
The Chick Embryo Chorioallantoic Membrane as an In Vivo Assay to Study Antiangiogenesis D Ribatti	Pharmaceuticals (Basel, Switzerland)	2010
Thiazolidinediones decrease vascular endothelial growth factor (VEGF) production by human luteinized granulosa cells in vitro DK Shah, KM Menon, LM Cabrera, A Vahratian, SK Kavoussi, DI Lebovic	Fertility and Sterility	2010
PPARs and the Cardiovascular System M Hamblin, L Chang, Y Fan, J Zhang, YE Chen	Antioxidants & Redox Signaling	2009
PPAR-gamma Agonists and Their Effects on IGF-I Receptor Signaling: Implications for Cancer A Belfiore, M Genua, R Malaguarnera	PPAR Research	2009
Prognostic and therapeutic potential of nuclear receptors in head and neck squamous cell carcinomas SK Knauer	Journal of Oncology	2009
DEHP effects on retinal vessels in newborn rats: a qualitative and quantitative analysis D Zei, A Pascarella, C Barrese, S Pantalone, S Stefanini	Histochemistry and Cell Biology	2009
Peroxisome proliferator-activated receptors as stimulants of angiogenesis in cardiovascular disease and diabetes Desouza CV, Rentschler L, Fonseca V	Diabetes, metabolic syndrome and obesity : targets and therapy	2009
PPARalpha agonist fenofibrate suppresses tumor growth through direct and indirect angiogenesis inhibition D Panigrahy, A Kaipainen, S Huang, CE Butterfield, CM Barnés, M Fannon, AM Laforme, DM Chaponis, J Folkman, MW Kieran	Proceedings of the National Academy of Sciences	2008
Enhanced angiogenesis in obesity and in response to PPARgamma activators through adipocyte VEGF and ANGPTL4 production O Gealekman, A Burkart, M Chouinard, SM Nicoloro, J Straubhaar, S Corvera	American journal of physiology. Endocrinology and metabolism	2008
The prince and the pauper. A tale of anticancer targeted agents A Dueñas-González, P García-López, LA Herrera, JL Medina-Franco, A González-Fierro, M Candelaria	Molecular Cancer	2008
Peroxisome Proliferator-Activated Receptor-gamma Ligands: Potential Pharmacological Agents for Targeting the Angiogenesis Signaling Cascade in Cancer C Giaginis, A Tsantili-Kakoulidou, S Theocharis	PPAR Research	2008
A Role for PPARbeta/delta in Ocular Angiogenesis D Bishop-Bailey	PPAR Research	2008
PPAR-γ, Microglial Cells, and Ocular Inflammation: New Venues for Potential Therapeutic Approaches F Malchiodi-Albedi, A Matteucci, A Bernardo, L Minghetti	PPAR Research	2008
Protective Actions of PPAR-γ Activation in Renal Endothelium PE Westerweel, MC Verhaar	PPAR Research	2008
Macrophages, PPARs, and Cancer JA van Ginderachter, K Movahedi, JV Bossche, PD Baetselier	PPAR Research	2008
Multiple Interactions between Peroxisome Proliferators-Activated Receptors and the Ubiquitin-Proteasome System and Implications for Cancer Pathogenesis D Genini, GM Carbone, CV Catapano	PPAR Research	2008
Clinical Use of PPARgamma Ligands in Cancer JL Hatton, LD Yee	PPAR Research	2008
PPARgamma and Agonists against Cancer: Rational Design of Complementation Treatments D Veliceasa, FT Schulze-Hoëpfner, OV Volpert	PPAR Research	2008
Rosiglitazone Suppresses the Growth and Invasiveness of SGC-7901 Gastric Cancer Cells and Angiogenesis In Vitro via PPARgamma Dependent and Independent Mechanisms Q He, R Pang, X Song, J Chen, H Chen, B Chen, P Hu, M Chen	PPAR Research	2008
PPARgamma: The Portrait of a Target Ally to Cancer Chemopreventive Agents I Sainis, K Vareli, V Karavasilis, E Briasoulis	PPAR Research	2008
Activated PPARgamma Targets Surface and Intracellular Signals That Inhibit the Proliferation of Lung Carcinoma Cells SW Han, J Roman	PPAR Research	2008
Peroxisome proliferator-activated receptors and progression of colorectal cancer D Wang, RN Dubois	PPAR Research	2008
The Roles of Dietary PPARgamma Ligands for Metastasis in Colorectal Cancer H Kuniyasu	PPAR Research	2008
Peroxisome proliferator activated receptor γ and oxidized docosahexaenoic acids as new class of ligand T Itoh, K Yamamoto	Naunyn-Schmiedeberg's Archives of Pharmacology	2008
Gene expression profile in colon cancer cells with respect to XIAP expression status L Qiao, GH Li, Y Dai, J Wang, Z Li, B Zou, Q Gu, J Ma, R Pang, HY Lan, BC Wong	International Journal of Colorectal Disease	2008
Thrombospondin and apoptosis: molecular mechanisms and use for design of complementation treatments Mirochnik Y, Kwiatek A, Volpert O	Current drug targets	2008
Angiogenesis modulates adipogenesis and obesity Yihai Cao	Journal of Clinical Investigation	2007
PPARα Deficiency in Inflammatory Cells Suppresses Tumor Growth A Kaipainen, MW Kieran, S Huang, C Butterfield, D Bielenberg, G Mostoslavsky, R Mulligan, J Folkman, D Panigrahy, M Blagosklonny	PloS one	2007
Peroxisome proliferator-activated receptors in lung cancer VG Keshamouni, S Han, J Roman	PPAR Research	2007
Inhibition of cell motility by troglitazone in human ovarian carcinoma cell line YC Yang, TC Ho, SL Chen, HY Lai, JY Wu, YP Tsao	BMC Cancer	2007
Peroxisome proliferator-activated receptor γ (PPARγ) and colorectal carcinogenesis IA Voutsadakis	Journal of Cancer Research and Clinical Oncology	2007
Synergy between PPARγ Ligands and Platinum-Based Drugs in Cancer GD Girnun, E Naseri, SB Vafai, L Qu, JD Szwaya, R Bronson, JA Alberta, BM Spiegelman	Cancer Cell	2007
Involvement of PPAR nuclear receptors in tissue injury and wound repair L Michalik, W Wahli	Journal of Clinical Investigation	2006
Effects of 15d-PGJ2 on VEGF-induced angiogenic activities and expression of VEGF receptors in endothelial cells P Funovics, C Brostjan, A Nigisch, A Fila, A Grochot, K Mleczko, H Was, G Weigel, J Dulak, A Jozkowicz	Prostaglandins & Other Lipid Mediators	2006
Growth factor signalling in prostatic growth: significance in tumour development and therapeutic targeting AR Reynolds, N Kyprianou	British Journal of Pharmacology	2006
PPARγ-independent induction of growth arrest and apoptosis in prostate and bladder carcinoma CL Chaffer, DM Thomas, EW Thompson, ED Williams	BMC Cancer	2006
Peroxisome-proliferator-activated receptor α agonists inhibit cyclo-oxygenase 2 and vascular endothelial growth factor transcriptional activation in human colorectal carcinoma cells via inhibition of activator protein-1 R Grau, C Punzón, M Fresno, MA Iñiguez	Biochemical Journal	2006
Cellular and Molecular Consequences of Peroxisome Proliferator-Activated Receptor-γ Activation in Ovarian Cancer Cells Vignati S, Albertini V, Rinaldi A, Kwee I, Riva C, Oldrini R, Capella C, Bertoni F, Carbone GM, Catapano CV	Neoplasia (New York, N.Y.)	2006
PPAR-gamma is expressed and NF-kB pathway is activated and correlates positively with COX-2 expression in stromal myofibroblasts surrounding colon adenocarcinomas GP Vandoros, PA Konstantinopoulos, G Sotiropoulou-Bonikou, A Kominea, GI Papachristou, MV Karamouzis, M Gkermpesi, I Varakis, AG Papavassiliou	Journal of Cancer Research and Clinical Oncology	2005
Thiazolidinediones inhibit proliferation of microvascular and macrovascular cells by a PPARgamma-independent mechanism M Artwohl, C Fürnsinn, W Waldhäusl, T Hölzenbein, G Rainer, A Freudenthaler, M Roden, SM Baumgartner-Parzer	Diabetologia	2005
PPAR-gamma activation inhibits angiogenesis by blocking ELR+CXC chemokine production in non-small cell lung cancer. Keshamouni VG, Arenberg DA, Reddy RC, Newstead MJ, Anthwal S, Standiford TJ	Neoplasia (New York, N.Y.)	2005
Crosstalk of oncogenic and prostanoid signaling pathways R Mller	Journal of Cancer Research and Clinical Oncology	2004
Antidiabetic thiazolidinediones inhibit invasiveness of pancreatic cancer cells via PPARgamma independent mechanisms A Galli, E Ceni, DW Crabb, T Mello, R Salzano, C Grappone, S Milani, E Surrenti, C Surrenti, A Casini	Gut	2004
Lack of efficacy of troglitazone at clinically achievable concentrations, with or without 9-cis retinoic acid or cytotoxic agents, for hepatocellular carcinoma cell lines YC Shen, C Hsu, JY Chen, AL Cheng	British Journal of Cancer	2004
Effect of peroxisome proliferator activated receptor gamma ligands on growth and gene expression profiles of gastric cancer cells WK Leung, AH Bai, VY Chan, J Yu, MW Chan, KF To, JR Wu, KK Chan, YG Fu, FK Chan, JJ Sung	Gut	2004
Pleiotropic effects of thiazolidinediones: Taking a look beyond antidiabetic activity S Giannini, M Serio, A Galli	Journal of Endocrinological Investigation	2004
Angiopoietin-like 4 is a proangiogenic factor produced during ischemia and in conventional renal cell carcinoma SL Jan, C Amy, A Cazes, C Monnot, N Lamandé, J Favier, J Philippe, M Sibony, JM Gasc, P Corvol, S Germain	The American Journal of Pathology	2003
Paracrine regulation of angiogenesis and adipocyte differentiation during in vivo adipogenesis D Fukumura, A Ushiyama, DG Duda, L Xu, J Tam, V Krishna, K Chatterjee, I Garkavtsev, RK Jain	Circulation research	2003
A phase II trial with rosiglitazone in liposarcoma patients G Debrock, V Vanhentenrijk, R Sciot, M Debiec-Rychter, R Oyen, AV Oosterom	British Journal of Cancer	2003

Advertisement